Evidence map›Paper›PMID 35276118›Full record

ArticleNeuropharmacology2022

NLX-112, a highly selective 5-HT

R Depoortère, J Bergman, P M Beardsley, R I Desai, C A Paronis, D M Walentiny, M A Varney, A Newman-Tancredi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Pharmacologic MRI Brain Imaging Studies of Serotonin 5-HTPharmacology research & perspectives · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

R DepoortèreNeurolixis SAS, 2 rue Georges Charpak, 81100, Castres, France. Electronic address: rdepoortere@neurolixis.com.
J BergmanMcLean Hospital, Behavioral Biology Program, Belmont, MA, 02478, USA.
P M BeardsleyDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA, 23298-0613, USA; Center for Biomarker Research and Precision Medicine, Virginia Commonwealth University, Richmond, VA, 23298-0613, USA.
R I DesaiMcLean Hospital, Behavioral Biology Program, Belmont, MA, 02478, USA.
C A ParonisMcLean Hospital, Behavioral Biology Program, Belmont, MA, 02478, USA.
D M WalentinyDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA, 23298-0613, USA.
M A VarneyNeurolixis SAS, 2 rue Georges Charpak, 81100, Castres, France.
A Newman-TancrediNeurolixis SAS, 2 rue Georges Charpak, 81100, Castres, France.
McLean Hospital · USVirginia Commonwealth University · USNeurolixis (United States) · US

Funding

IGF::OT::IGF ASSESSMENT OF POTENTIAL SUBSTANCE ABUSE TREATMENT MEDICATIONS IN NONHUMAN PRIMATE MODELS. NIDA REF. NO. N01DA-19-8946; POP: 12/16/2018-12/15/2019. PURPOSE: TO EXERCISE OPTION QUANTITIES 175N95019C00007 · NIDA · MCLEAN HOSPITAL · PI BERGMAN, JACK · 2019 to 2023
$6.1M
NIDA NIH HHS 75N95019C00007NIDA NIH HHS HHSN271201700008C
6 · The paper itself

Abstract

NLX-112 (a.k.a. F13640 or befiradol) exhibits nanomolar affinity, exceptional selectivity and biased agonism at serotonin 5-HT

Indexed as

MacacaPiperidinesPyridinesSerotonin 5-HT1 Receptor AgonistsAnimalsHumansLevodopaMaleRatsReceptor, Serotonin, 5-HT1AbefiradolLevodopaPiperidinesPyridinesReceptor, Serotonin, 5-HT1ASerotonin 5-HT1 Receptor Agonists5-HT(1A) receptorsCocaine drug discriminationIntracranial self-stimulationl-DOPA-induced dyskinesiaMisuse potentialNLX-112

Identifiers

PMID35276118
PMCPMC8996383
OpenAlexW4221070675

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.